Haemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Haemophilia A, Haemophilia B, Haemophilia C), By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI therap
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationHaemophilia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Haemophilia A, Haemophilia B, Haemophilia C), By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI therap
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 11.34 Billion |
| CAGR (2023-2028) | 5.73% |
| Fastest Growing Segment | Haemophilia A |
| Largest Market | North America |
Market Overview
Key Market Drivers
Increasing Predominance of Hemophilia
New Products and Medication Launches
Growth in Hemophilia Inhibitors
Surging Trend Of Prophylaxis Treatment
Key Market Challenges
High Cost Linked with Hemophilia Treatment
Low Adoption Rates Of Technologically Advanced Products In Developing Countries
Key Market Trends
Collaborative Research and Drug Development
Gene Therapy Advancements
Segmental Insights
Type Insights
In 2022, Hemophilia A emerged as the dominant player in the hemophilia market, capturing the highest share. This genetic disorder is characterized by a deficiency in blood clotting factor VIII, leading to prolonged bleeding episodes. The prevalence of hemophilia A in developed regions, coupled with supportive government initiatives, has been instrumental in driving its market dominance. Major markets such as the U.S., Europe, and Japan have witnessed the launch of innovative products, further bolstering the market position of Hemophilia A. According to a survey conducted by the World Federation of Hemophilia (WFH) in 2020, countries like the U.S., India, and Brazil have reported a significant number of Hemophilia A cases, estimated to be around 10,000. This underscores the pressing need for effective treatment and management strategies to address this complex genetic disorder.
On the other hand, Hemophilia B is expected to exhibit steady growth during the forecast period. This variant of hemophilia is characterized by a deficiency in blood clotting factor IX. The market growth of Hemophilia B can be attributed to a robust pipeline of innovative products and the advent of gene therapy. Notably, in February 2023, the European Commission granted conditional approval to CSL Behring's gene therapy Hemgenix for the treatment of Hemophilia B. This milestone approval follows the product's successful launch in the U.S. market, where it is found at at a price point of USD 3.5 million for a one-time treatment. These advancements in the treatment landscape hold promising prospects for individuals living with hemophilia, offering them improved quality of life and enhanced disease management options.
Treatment Insights
Based on the type of treatment, the treatment and hemophilia market is divided into two main categoriesprevention and on-demand treatment. On-demand treatment, which involves administering medication when bleeding episodes occur, held the largest market share in 2022. However, the prevention segment is expected to experience the highest growth rate during the forecast period.
One commonly used and widely accepted form of preventive treatment is prophylaxis, which involves regular injections of coagulation factor concentrate. Prophylaxis has shown significant efficacy in managing severe hemophilia and has the potential to improve the growth rate of this market. The duration of prophylactic treatment varies depending on the severity of the patient's condition, and it aims to reduce productivity losses and enhance the overall quality of life for individuals with hemophilia.
By providing a consistent and proactive approach to managing bleeding episodes, prophylactic treatment holds promise in minimizing the impact of hemophilia on patients' daily lives. Its ability to prevent or reduce bleeding episodes not only improves physical well-being but also positively impacts emotional and social aspects of life for individuals living with this condition.
Regional Insights
Recent Developments
- BioMarinPharmaceutical Inc. presented favorable outcomes from a comprehensive two-yearanalysis of the Phase 3 GENEr8-1 study, along with an overall safety update ofvaloctocogene roxaparvovec, an investigational gene therapy for severehaemophilia A, at the 15th Annual Virtual Congress of the European Associationfor Haemophilia and Allied Disorders (EAHAD) in April 2022.
- In March 2022,Freeline Therapeutics Holdings plc initiated dosing of the inaugural patient inits Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for themanagement of hemophilia B, a debilitating genetic bleeding disorder caused bya deficiency in the clotting factor IX protein.
- During the 15thAnnual Virtual Congress of the European Association for Haemophilia and AlliedDisorders (EAHAD) in February 2022, BioMarin Pharmaceutical Inc. unveiledencouraging results from a comprehensive two-year analysis of the Phase 3GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, aninvestigational gene therapy for adults with severe hemophilia A.
Key Market Players
- Bayer AG
- BioMarin Pharmaceutical, Inc.
- CSL Behring LLC
- Kedrion S.p.A
- Novo Nordisk A/S
- Pfizer, Inc.
- Octapharma AG
- Sanofi S.A.
- Takeda Pharmaceutical Company
- Grifols SA
| By Type | By Product | By Treatment | By Therapy | By Region |
| |
|
|
|
|
| ||
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy